Beta Bionics (BBNX) Stock: Buy, Sell, or Hold?
BBNX - Beta Bionics, Inc. Common Stock
$18.96
0.09 (0.48%)
▲
5d:
-11.85%
30d:
-2.34%
90d:
+13.4%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 27, 2026
23d
Get Alerted When BBNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BBNX is down 11.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BBNX is down 11.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BBNX is currently trading at $18.96, which is considered fair relative to its 30-day fair value range of $18.16 to $21.56.
Technical Outlook: Technically, BBNX is in a strong uptrend. Immediate support is located at $18.27, while resistance sits at $23.56.
Market Sentiment: BBNX scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.28 (+22.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BBNX is in a strong uptrend. Immediate support is located at $18.27, while resistance sits at $23.56.
Market Sentiment: BBNX scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.28 (+22.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$18.16 -
$21.56
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (21/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 22.8% below Wall St target ($23.28)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$18.16 -
$21.56
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$18.27
Resistance Level
$23.56
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.15
Wall Street Target
$23.28
(+22.8%)
Revenue Growth (YoY)
37.8%
Profit Margin
-61.3%
Share & Embed Analysis
Last updated: October 02, 2026 8:41 PM ET
Data refreshes hourly during market hours. Next update: 9:41 PM
Data refreshes hourly during market hours. Next update: 9:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BBNX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 69 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 64 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 58 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 38 SELL |
